UA139846U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes a clinical examination, radiography. Additionally, the patient's serum determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTHFR C677T), the content of endothelin, folic acid, transforming growth factor beta 1 (TGF-1), C-reactive protein (SRP), interleukin 6 (IL-6). With a homozygous carrier of 677-TT and endothelin levels> 10 ng / ml, folic acid <6 ng / ml, TGF- / 1 <14 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l predict the development osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. M, 2001. - vol. 2. - pp. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, folic acid, transforming growth factor beta 1 is additionally determined in the patient's blood serum (TGF-RI1), C-reactive protein (CRP), interleukin 6 (IL-6) and with homozygous carrier 677-

TI and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, TFR-D1" 14 ng/ml, SRP "6 mg/l, IL-6 210 ng/l predict the development of osteoarthritis.

The method is used as follows.

During hospitalization, the patient is examined, x-rays are taken, and the MTNEK S677T gene polymorphism is determined. The content of endothelin, folic acid,

TFR-VI, SRP, IL-6. With homozygous carrier 677-TT, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, TFR-VI1" 14 ng/ml, SRP 26 mg/l, IL-b6 "10 ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient D., 69 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found.

The polymorphism of the MTNEK C677T gene was determined in the blood serum. The content of endothelin, folic acid, TFR-B1I, SRP, IL-6 was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of endothelin - 23 ng/ml, folic acid - 2.8 ng/ml, TGF-VD1 - 7.2 ng/ml,

From SRP - 14 mg/l, IL-b6 - 25 ng/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK Сб677Т), the content of endothelin, folic acid, transforming growth factor beta 1 (TGF-RI) is additionally determined ), C-reactive protein (SRP), interleukin 6 (IL-6) and with homozygous carrier 677-171 and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, TGF-DRI "14 ng/ml, SRP »6 mg/l, IL-6 »10 ng/l predict the development of osteoarthritis.